Linden Adds Operating Partner

Linden Capital Partners has added Joseph Bernardo to its team as a new Operating Partner.

Mr. Bernardo has significant M&A experience and has been involved with over 25 due diligences, acquisitions, and integrations since the start of his career. He most recently served as the President of the Next-Generation Sequencing and Oncology division at Thermo Fisher Scientific. Mr. Bernardo has been with Thermo Fisher since 2008 and in addition to his work with next-generation technologies he was the president of the company’s ImmunoDiagnostics, Anatomic Pathology, and Fisher Healthcare divisions. Prior to joining Thermo Fisher, he served as the Senior Vice President of the Central Lab Business Unit at Siemens Healthcare. Mr. Bernardo holds a BS in Chemistry from Lafayette College and a MA in Chemistry from the University of Virginia. He is currently a Senior Advisor to The Boston Consulting Group.

“After spending my career with Thermo Fisher, Siemens, and Abbott, I am excited to partner with a healthcare exclusive private equity firm that respects and values my management, operational, R&D, and M&A experience in the diagnostics industry,” said Mr. Bernardo.

Mr. Bernardo will serve as the Chairman of SeraCare and will also act as the lead Operating Partner for Linden’s investments in future diagnostics and life sciences companies. Linden acquired SeraCare, a maker of diagnostic controls, reagents and molecular biomarkers used in a variety of in vitro diagnostics, in April 2012.

“Joe has a plethora of relevant experience and brings an unparalleled knowledge base in the diagnostics arena,” said Brian Miller, a Managing Partner at Linden. “We are thrilled for him to join SeraCare as Chairman and continue to build upon Linden’s expertise in diagnostics.”

Linden Capital Partners is focused exclusively on leveraged buyouts in the healthcare and life science industries with a specific interest in medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden’s strategy is based upon three elements: healthcare and life science industry specialization; integrated financial and operating expertise; and strategic relationships with large corporations. The firm is based in Chicago (www.lindenllc.com).

© 2018 Private Equity Professional | January 3, 2018

Print Friendly, PDF & Email

Related Articles

Abacus Backs River’s Buy of GAHH Abacus Finance Group was the Administrative Agent and Lead Arranger for $22 million in senior secured credit facilities to support the recent acquisit...
New Partner at Trive Capital Trive Capital has promoted Blake Bonner to Partner. Mr. Bonner’s responsibilities include identifying and evaluating investment opportunities, perform...
Genstar Promotes Two Genstar Capital has promoted Geoff Miller to Director and Rob Clark to Principal. “We are pleased to announce the promotions of Geoff and Rob,” sai...
New Managing Director at Grey Mountain Grey Mountain Partners has promoted Beth Lesniak to Managing Director. Ms. Lesniak joined Grey Mountain in 2009 and she is active in all areas of t...
The Seller’s Market Continues High valuations and abundant use of debt continued to mark completed deal activity in the first quarter of 2018, according to GF Data’s just-released ...
Drew Meyers Rejoins Seaport Seaport Capital has added Drew Meyers to its investment team as a new partner. Mr. Meyers previously worked at Seaport from 2001 to 2007. We are ex...